Brief: Orexo Announces Positive Results From Pivotal Trial For Its Leading Pharmaceutical Pipeline Asset OX124

Orexo AB

16/11/2021 07:05

Nov 16 (Reuters) - Orexo AB  ORX.ST :
    * OREXO ANNOUNCES POSITIVE RESULTS FROM PIVOTAL TRIAL FOR
ITS
LEADING PHARMACEUTICAL PIPELINE ASSET OX124
    * TRIAL OX124-002 MEETS PRIMARY ENDPOINTS IN 4-PERIOD
CROSSOVER,
COMPARATIVE BIOAVAILABILITY STUDY IN HEALTHY VOLUNTEERS
    * OX124 SHOWED A SIGNIFICANTLY FASTER AND HIGHER ABSORPTION
OF
NALOXONE COMPARED TO INTRAMUSCULAR DOSING WITH INJECTION
REFERENCE PRODUCT
    * IS EXPECTING TO FILE A NEW DRUG APPLICATION WITH US FOOD
AND
DRUG ADMINISTRATION (FDA) IN H2 2022
    * FOLLOWING FDA APPROVAL, A US LAUNCH WILL BE INITIATED IN
H2 2023

Source text for Eikon:  ID:nWkr3trbkr 
Further company coverage:  ORX.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))